Market Insight - ThromboGenics: a biotech tale of four cities
This article was originally published in Scrip
Rare is the biotech firm founded on a multi-million euro royalty stream. Gerhard Symons relates the unusual story of a Belgian company with a flair for European dealmaking
You may also be interested in...
Dr Jonathan Knowles, president of group research at Roche, tells Gerhard Symons about optimising Roche's R&D, the company's partnership strategies, and his personal crusade from day one: personalised healthcare